Dr. Fonzo has served as a consultant for SynapseBio AI and Alto Neuroscience; he has received research support from the Brain and Behavior Research Foundation, the One Mind Baszucki Brain Research Fund, and the SEAL Future Foundation; he is named as an inventor on a patent application related to the treatment of depression; and he is a stockholder in Alto Neuroscience. Dr. Krystal serves on the editorial board of Biological Psychiatry; he is co-founder of Freedom Biosciences; he has served on scientific advisory boards for Biohaven Pharmaceuticals, BioXcel Therapeutics (clinical advisory board), Cerevel Therapeutics, Delix Therapeutics, Eisai, EpiVario, Jazz Pharmaceuticals, Neumora Therapeutics, Neurocrine Biosciences, Novartis, PsychoGenics, Takeda, Tempero Bio, and Terran Biosciences; he has received in-kind research support (medications) from AstraZeneca, Cerevel, Novartis; he has served as a consultant for Aptinyx, Biogen Idec MA, Bionomics, Boehringer Ingelheim International, Epiodyne, EpiVario, Janssen Research & Development, Jazz Pharmaceuticals, Otsuka America Pharmaceutical, Spring Care, and Sunovion Pharmaceuticals; he is named on patents related to various mental disorders, including schizophrenia, depression, suicidal ideation, addiction, and gambling and gaming disorders; and he holds stock or stock options in Biohaven Pharmaceuticals, Cartego Therapeutics, Damona Pharmaceuticals, Delix Therapeutics, EpiVario, Freedom Biosciences, Neumora Therapeutics, Response Pharmaceuticals, Rest Therapeutics, Spring Health, Tempero Bio, Terran Biosciences, and Tetricus. Dr. Carpenter has received research support from Janssen, Neuronetics, Neurolief, and Nexstim, and she has served as a consultant for Janssen, Magnus Medical, MAPS Public Benefit Corp, Motif Neurotech, Neuronetics, Neurolief, Otsuka, and Sage Therapeutics. Dr. McDonald and Dr. Rodriguez are Deputy Editors for the American Journal of Psychiatry; the Editors’ disclosures appear in the April 2024 issue of the Journal. Dr. Grzenda serves on the Editorial Board of the Journal (statistical editor) and has served as a consultant for the American Psychiatric Association. Dr. Widge has received research support from the Minnesota Medical Discovery Team on Addictions and the MnDRIVE Brain Conditions Initiative. Dr. Nemeroff has served as a consultant for AbbVie, ANeuroTech (division of Anima BV), BioXcel Therapeutics, Clexio, EMA Wellness, EmbarkNeuro, Engrail Therapeutics, Galen Mental Health, GoodCap Pharmaceuticals, Intra-Cellular Therapies, Relmada Therapeutics, Sage, Senseye, Signant Health, and Silo Pharma; he is a stockholder in Corcept Therapeutics, EMA Wellness, Galen Mental Health, Precisement Health, Relmada Therapeutics, and Seattle Genetics; he has served on scientific advisory boards for ANeuroTech, the Brain and Behavior Research Foundation, the Laureate Institute for Brain Research, Sage, Signant Health, and Skyland Trail and on the board of directors for Lucy Scientific Discovery; and he is named on patents related to psychiatric treatment.